MediPal Holdings (7459) Q1 2026 earnings summary

Executive summary

• Net sales rose 3.9% year-over-year to ¥945.1 billion, with all business segments contributing to growth.

• Operating profit increased 5.8% year-over-year to ¥14.0 billion, driven by higher gross profit and controlled SG&A expenses.

• Profit attributable to owners of parent grew 6.4% year-over-year to ¥9.5 billion, aided by gains from selling investment securities.

• Strategic investments and business restructuring expenses, particularly in logistics, impacted results.

• Comprehensive income fell 35.1% year-over-year to ¥9.8 billion, mainly due to lower valuation on securities.

Financial highlights

• Gross profit increased by ¥2.0 billion year-over-year, with a gross margin of 6.84%.

• Ordinary profit reached ¥18.2 billion, up 7.8% year-over-year.

• EPS for the quarter was ¥46.17, up from ¥42.96 a year earlier.

• Extraordinary income included ¥0.8 billion from gains on sales of investment securities; extraordinary losses of ¥0.9 billion were related to logistics restructuring.

• SG&A expenses rose by ¥1.3 billion, mainly due to investments in human resources and logistics.

Outlook and guidance

• Full-year net sales forecast at ¥3,785.0 billion, up 3.1% year-over-year.

• Operating profit projected at ¥52.0 billion (+6.5%), ordinary profit at ¥69.0 billion (+5.7%), and profit attributable to owners of parent at ¥34.5 billion (+14.3%).

• EPS for the year forecast at ¥167.28, factoring in a planned share buyback.

• Dividend payout planned at ¥64.00 per share for the full year.